Foundation Medicine H1 Revenues Rise Sharply as it Awaits IPO | GenomeWeb

NEW YORK (GenomeWeb News) – Foundation Medicine's revenues through the first half of 2013 increased 363 percent year over year, the company said in its amended Form S-1 on Friday.

The Cambridge, Mass.-based firm, which filed to go public almost three weeks ago, said that revenues through June 30 rose to $11.1 million, compared to $2.4 million during the year-ago period. Net loss for the six months increased to $17.4 million from $11.3 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.